CVS Health (NYSE:CVS) Price Target Raised to $118.00

CVS Health (NYSE:CVS) had its target price increased by JPMorgan Chase & Co. from $111.00 to $118.00 in a report published on Wednesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the pharmacy operator’s stock.

Several other analysts also recently issued reports on the stock. UBS Group increased their price objective on shares of CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. HSBC restated a “hold” rating and issued a $103.00 target price on shares of CVS Health in a research note on Monday, July 6th. Weiss Ratings raised shares of CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Argus increased their target price on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Finally, Barclays boosted their price objective on CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $106.75.

CVS Health Price Performance

CVS Health stock opened at $97.09 on Wednesday. CVS Health has a 1 year low of $67.42 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a 50 day moving average price of $102.52 and a 200 day moving average price of $88.23. The company has a market cap of $124.18 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 0.91 and a beta of 0.61.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts predict that CVS Health will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

Insider Transactions at CVS Health

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 3,372,000 shares of company stock valued at $317,473,598 in the last ninety days. 0.85% of the stock is owned by insiders.

Hedge Funds Weigh In On CVS Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of CVS Health in the second quarter valued at approximately $12,747,462,000. Norges Bank acquired a new position in shares of CVS Health in the 4th quarter valued at $1,666,265,000. Wellington Management Group LLP lifted its holdings in shares of CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after acquiring an additional 12,233,675 shares during the period. Pzena Investment Management LLC bought a new position in CVS Health during the second quarter worth about $1,217,558,000. Finally, Legal & General Group Plc acquired a new position in CVS Health during the second quarter worth $948,947,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.